Drug Trial Radar · NCT06194734
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Last checked: Nov 19, 2026Latest source record: Mar 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
490
Planned (sponsor's estimate)
Start
Feb 5, 2024
Primary completion
Dec 30, 2026
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of KC1036 versus investigator's choice of chemotherapy in patients with advanced recurrent or metastatic esophageal squamous cell carcinoma
Conditions
- Esophageal Squamous Cell Carcinoma
Interventions
KC1036Drug
KC1036 60mg QD orally, before a meal, continuous administration, 21 days as a cycle
IrinotecanDrug
Irinotecan intravenously administered at 130-150 mg/m2 once every 2 weeks
DocetaxelDrug
Docetaxel intravenously administered at 60-75 mg/m2 once every 3 weeks;
S-1Drug
S-1 orally administered 40-60mg Bid on Day 1 to Day 14 of every 3 weeks, 21 days as a cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Baseline to study completion (approximately 24 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.